{
    "organizations": [],
    "uuid": "37637750985a6dead169128ccdc328f0a7168f3c",
    "author": "Alberto Delclaux",
    "url": "https://www.wsj.com/articles/novartis-to-buy-gene-therapy-company-avexis-for-8-7-billion-1523251511",
    "ord_in_thread": 0,
    "title": "Novartis Bets $8.7 Billion on Gene-Therapy Company",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Novartis AG agreed to buy U.S.-based gene-therapy company AveXis Inc. for $8.7 billion, marking the first big bet by the Swiss pharmaceutical giant’s new chief as he looks to the deal table to refresh his drug-development pipeline. \n\nNovartis said Monday it will pay $218 for each share in Illinois-based AveXis, an 88% premium to its closing price on April 6. Earlier this year, Novartis Chief Executive Vasant Narasimhan agreed to cash out of its consumer health joint venture with GlaxoSmithKline PLC—a deal that gives him cash...  ",
    "published": "2018-04-09T11:13:00.000+03:00",
    "crawled": "2018-04-09T11:04:48.022+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "novartis",
        "ag",
        "agreed",
        "buy",
        "company",
        "avexis",
        "billion",
        "marking",
        "first",
        "big",
        "bet",
        "swiss",
        "pharmaceutical",
        "giant",
        "new",
        "chief",
        "look",
        "deal",
        "table",
        "refresh",
        "pipeline",
        "novartis",
        "said",
        "monday",
        "pay",
        "share",
        "avexis",
        "premium",
        "closing",
        "price",
        "april",
        "earlier",
        "year",
        "novartis",
        "chief",
        "executive",
        "vasant",
        "narasimhan",
        "agreed",
        "cash",
        "consumer",
        "health",
        "joint",
        "venture",
        "glaxosmithkline",
        "deal",
        "give",
        "cash"
    ]
}